We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mrs
Sayyora
Alieva
sayyorakhon.alieva@nhs.net
Dr
Helena
Marzo-Ortega
h.marzo-ortega@leeds.ac.uk
Inflammatory polyarthropathiesSpondylopathiesPapulosquamous disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Axial spondyloarthritis and psoriatic arthritis are part of a group of life-long inflammatory conditions, called the seronegative spondyloarthropathies (SpAs). These diseases occur when the body’s immune system, which usually defends against infection, starts attacking healthy joints causing inflammation, bone damage and pain. If untreated, this inflammation may cause permanent joint damage and disability.
We know that genes play an important role in who gets SpA. However, there are hundreds more to be discovered. If we know the genes that are important for developing SpA, this could allow doctors to speed up diagnosis, screen relatives to identify who may be at risk of the condition, and even to predict which drug is going to work best for which patient. This is sometimes called personalised medicine.
This study is open to all Leeds Teaching Hospitals patients who have a diagnosis of axial spondyloarthritis or psoriatic arthritis.
Patients donate a one-off blood sample and give permission for this to be analysed for a range of common genetic markers. This information will be linked with the clinical information from the patient record to explore which genes are linked with SpA and treatment response.
Other important information for patients:
• Participants can sign up to the study and donate a blood sample on the same day as their regular clinic appointment.
• Participants do not have to attend extra clinic appointments to take part in the study.
• Taking part in the study will not delay any treatment Participants might need on the day. Participants will still have the same blood tests, scans and medication required.
• Unfortunately, it is not possible to provide Participants the results of the genetics test.
• Once Participants provide a blood sample, this is given a unique/pseudonymised study number. This means that no one from the study team knows which Participant the blood was taken from when they analyse the results.
• Taking part will not affect insurance applications in any way. Participants do not need to tell insurers that they are part of this study.
Where can I take part?
• If you are interested in taking part, speak to your doctor at your next rheumatology outpatient appointment at Leeds Teaching Hospitals NHS Trust.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Not Specified;
You can take part if:
You may not be able to take part if:
• Not a patient at the Leeds Specialist Spondyloarthritis Service • Under the age of 18 • Unable to attend the clinic in person to sign the study consent form and donate a one-off blood samples for research.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by LEEDS TEACHING HOSPITALS NHS TRUST and funded by VERSUS ARTHRITIS .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 6231
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
